Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human KIT Antibodies:
Go to our pre-filtered search.
the missense mutation p.Arg682His, the g.77784972T>C variant at KIT and the g.20147039C>T variant at MITF (show MITF Antibodies) are the main influence on the extent of white facial markings
Accumulating mutations in series of haplotypes at the KIT and MITF (show MITF Antibodies) loci are major determinants of white markings in Franches-Montagnes horses.
FGF7 (show FGF7 Antibodies) may be an important regulator for oocyte growth and its action is mediated via the KIT/KITLG (show KITLG Antibodies) signaling pathway.
c-kit is primarily expressed in the spermatogonia and spermatocytes of goat testes.
mRNA expression of c-kit and SCF was decreased in gallbladder tissues in the HCD group. Consistent with the findings of RT-PCR, a lower expression level of c-kit and SCF protein was also observed in HCD animals.
Delayed enrichment for c-kit and inducing cardiac differentiation attenuated protective effects of BMSCs' transplantation in pig model of acute myocardial infarction.
Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and cKit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle.
Multivariate analysis showed that KIT-AL and TET2 (show TET2 Antibodies) mutations were associated with inferior LFS, whereas age 40 years and marrow blast 70% were associated with inferior OS.
the critical physiological role of the KIT-ET3 (show EDN3 Antibodies)-NO pathway in fulfilling high demand (exceeding basal level) of endothelium-dependent NO generation for coping with atherosclerosis, pregnancy, and aging, is reported.
determined that miR (show MLXIP Antibodies)-137 can participate in the leukemogenesis by regulating c-kit, which could be used as a therapeutic target for acute myeloid leukemia (show BCL11A Antibodies)
Report up-regulation of the mTOR (show FRAP1 Antibodies), PDGF (show PDGFA Antibodies), VEGF (show VEGFA Antibodies), and c-kit pathways in a large cohort of Kaposi sarcoma samples.
c-KIT overexpressing cells showed a regression of typical morphological features of malignancy. Taken together these results suggest that c-KIT could be involved in the differentiation of thyroid cells and in tumor progression
low level of MITF (show MITF Antibodies) cooperates with oncogenic KIT to transform melanocytes. Activation of the cAMP pathway in transformed (L576P)KIT melanocytes stimulated MITF (show MITF Antibodies) expression, and reduced cellular proliferation and sphere formation. These findings highlight the essential role of MITF (show MITF Antibodies) in revealing the oncogenic activity of KIT in melanocytes and suggest that the cAMP pathway is a therapeutic target in KIT-mutated melanoma.
This previously unexplored G4-G4 interaction modulates both the conformation and the stability of the overall arrangement of the c-KIT promoter. It is not supported by stacking of single nucleotides but refers to a G4-G4 interaction surface surrounded by a two-nucleotides loop that might represent a reliable unprecedented target for anticancer therapy.
Transcription factor-induced activation of cardiac gene expression in human c-kit+ cardiac progenitor cells has been reported.
It was found that the absence of mutations in the SRSF2 (show SRSF2 Antibodies), ASXL1 (show ASXL1 Antibodies), and/or RUNX1gene panel at baseline and a reduction of the KIT D816V allele burden more than 25% at month 6 are the most favorable predictors for improved survival in midostaurin-treated advanced systemic mastocytosis patients.
Point mutation in c-kit gene is associated with sequential development of an ovarian mixed germ cell tumor and systemic mastocytosis with chronic myelomonocytic leukemia.
This gene encodes the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. This protein is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene.
c-kit receptor tyrosine kinase
, mast/stem cell growth factor receptor
, protein kinase
, tyrosine kinase receptor homolog
, c-kit-related protein
, kit-related kinase 1
, mast/stem cell growth factor receptor-related protein Kit
, proto-oncogene tyrosine-protein kinase Kit-related protein
, tyrosine-protein kinase Kit
, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
, Mast/stem cell growth factor receptor
, mast/stem cell growth factor receptor Kit
, transmembrane tyrosine kinase receptor
, proto-oncogene c-Kit
, c-kit receptor
, mast cell growth factor receptor
, proto-oncogene tyrosine-protein kinase Kit
, receptor tyrosine kinase c-kit
, c-KIT gene1
, Proto-oncogene c-Kit
, Tyrosine-protein kinase Kit
, caprine c-kit protein
, p145 c-kit
, piebald trait protein
, soluble KIT variant 1
, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein